Antifibrotic Drug Development Summit on November 17-19, 2025 in Boston, United States

The antifibrotic field is at an inflection point: Madrigal’s Resmetirom secured the first-ever MASH approval in 2024, Boehringer’s nerandomilast hit its Phase 3 endpoint in IPF, and pharma giants like Lilly and GSK are investing billions in fibrosis pipelines. Yet, with GLP-1s reshaping metabolic disease treatment and organ-specific challenges persisting, developers must now prove differentiation, whether through novel targets, biomarker strategies, or pan-fibrotic mechanisms.

Tackle these shared challenges alongside 80+ leaders from Pfizer, Novartis, Gilead Sciences, and pioneering biotechs at the 9th Antifibrotic Drug Development Summit - the only cross-fibrosis industry summit bridging discovery to Phase 2, across IPF, MASH, kidney, cardiac, and systemic sclerosis fibrosis.

URLs:

Brochure: https://go.evvnt.com/3178913-0?pid=10008

Tickets: https://go.evvnt.com/3178913-3?pid=10008

Time: 8:30 AM - 3:30 PM

Prices:

Academic - Conference Only: USD 2599.00,

Academic - Conference + Workshop Day: USD 3597.00,

Solution Provider Pricing - Conference Only: USD 3699.00,

Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Drug Developer Pricing - Conference + Workshop Day: USD 4197.00

Speakers: Ahmed Mousa, Chief Executive Officer, Vicore Pharma, Anna Zagorska, Director, Inflammation and Fibrosis, Gilead Sciences, Caroline Phillips, Chief Scientific Officer, RedX Pharma, Daniel Wilcock, Principal Translational Scientist, RedX Pharma, Dori Thomas-Karyat, Chief Executive Officer, Synthis Therapeutics, Gary Sweeney, President and Professor, Toronto BioScience Inc and York University, Henrik Landgren, Scientific Director, Precision Medicine Immunology and Fibrosis, Abbvie, Jeffrey Bornstein, Chief Medical Officer, Mediar Therapeutics, Jen-Chieh Chuang, Program, Translational Medicine and Biomarker Lead, Takeda Pharmaceutical, John Nicosia, Chief Operating Officer, Vasarya Therapeutics, Katie McCauley, Director and Portfolio Strategy and Fibrosis Research Lead, Novartis, Kevin Hart, Associate Research Fellow, Scientific Director, Fibrosis Exploratory Biology and Drug Discovery Group, Pfizer, Lee Borthwick, Chief Operating Officer, FibroFind, Leslie Nangle, Vice President, Research, aTyr Pharma Inc., Louise Goksøyr, Project Lead and Scientist, AdaptVac, Mehrsa Mehrabi, Senior Scientist, Viscient Biosciences, Min Lu, Executive Director, Eli Lilly and Co., Rebecca Taub, Chief Executive Officer, Madrigal Pharmaceuticals, Remi Laberge, CTO, Arda Therapeutics, Rob Menzies, Senior Director, AstraZeneca, Rui Wu, Chief Officer ,Senior Vice President and Head of Research and Preclinical ,Chemistry, Manufacturing and Controls, Graviton BioScience, Sydney Montesi, Pulmonary and Critical Care Medicine Physician, Massachusetts General Hospital, Vipin Kumar, Co-Founder and Chief Scientific Officer, GRI Bio, Yury Popov, Co-Director, Pathogens Immunity and Inflammation Translational Hub and Associate Professor, Medicine, Beth Israel Deaconess Medical Center